Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 231

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 6
Chunk 231
---
 Member of the Broad Institute. She presently serves on the advisory boards of Rockefeller University, the Howard Hughes Medical Institute, Genentech, Pfizer, Amgen, Janssen and Goldman Sachs Life Sciences (amongst others), and of several research institutes worldwide. Diane Mathis was elected to the U. S. National Academy of Sciences in 2003, the German Academy in 2007, and the American Academy of Arts and Sciences in 2012. She received the Excellence in Science Award from the Federation of American Societies in Experimental Biology in 2016, the inaugural Menarini Prize for outstanding Woman Immunologist from the International Union of Immunological Societies in 2023 and the William B Coley Award for Distinguished Research in Basic Immunology from the Cancer Research Institute in 2024. Her lab works in the fields of T cell differentiation, immunological tolerance, autoimmunity and inflammation. She has trained over 175 students and postdoctoral fellows from all over the world.

Miriam Merad, M. D., Ph. D., is Director of the Precision Immunology Institute at Mount Sinai School of Medicine in New York (PrIISM), Inaugural chai of the Department of Immunology and Immunotherapy and the Director of the Mount Sinai Human Immune Monitoring Center (HIMC). Miriam Merad is an internationally renowned physician-scientist with expertise in human disease immunology. Miriam Merad has identified the tissue-resident macrophage lineage and revealed its distinct role in organ physiology and pathophysiology. She has demonstrated the contribution of this macrophage lineage to cancer progression and inflammatory diseases. She is currently working on the development of new therapies targeting macrophages for these pathologies. In addition to her work on macrophages, Miriam Merad is known for her work on dendritic cells, a group of cells that control adaptive immunity. She has identified a new subset of dendritic cells, which is now considered to be a key target for antiviral and antitumor immunity. Miriam Merad is the author of more than 300 articles and reviews in leading journals. Her work has been cited several thousand times. She is an elected member of the American Society of Clinical Investigation and has received the William B. Coley Award for her contributions to the field of cancer immunology. She is an elected member of the U. S. National Academy of Sciences and in 2023 to the U. S. National Academy of Medicine and a Fellow of the AAC